Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions

被引:76
作者
Tosteson, ANA
Jönsson, B
Grima, DT
O'Brien, BJ
Black, DM
Adachi, JD
机构
[1] Dartmouth Coll Sch Med, Dept Med, Hanover, NH USA
[2] Dartmouth Coll Sch Med, Ctr Evaluat Clin Sci, Dept Community & Family Med, Hanover, NH USA
[3] Stockholm Sch Econ, Ctr Hlth Econ, S-11383 Stockholm, Sweden
[4] Innovus Res Inc, Burlington, ON, Canada
[5] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada
[6] St Josephs Hosp, Ctr Evaluat Med, Hamilton, ON, Canada
[7] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
[8] McMaster Univ, St Josephs Hosp, Dept Med, Hamilton, ON, Canada
关键词
cost-effectiveness analysis; decision analysis; osteoporosis; postmenopausal women; quality of life; risk factors;
D O I
10.1007/s001980170036
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Assessing the cost-effectiveness of long-term treatment for osteoporosis requires use of mathematical models to estimate health effects and costs for competing interventions. The primary motivations for model-based analyses include the lack of long-term clinical trial outcome data and the lack of data comparing all relevant treatments within randomized clinical trials. We report on specific modeling challenges that arose in the development of a model of the natural history of postmenopausal osteoporosis that is suitable for assessing the cost-effectiveness of osteoporosis interventions among various population subgroups in diverse countries. These include choice of modeling changes in bone mineral density (BMD) or in fracture rate, definition of health states, modeling mortality and costs of long-term care following fracture, incorporation of health utility, and model validation. This report should facilitate future postmenopausal osteoporosis model development and provide insight for decisionmakers who must evaluate model-based economic analyses of postmenopausal osteoporosis interventions.
引用
收藏
页码:849 / 857
页数:9
相关论文
共 56 条
[1]   Users' guides to the medical literature XIX. Applying clinical trial results A. How to use an article measuring the effect of an intervention on surrogate end points [J].
Bucher, HC ;
Guyatt, GH ;
Cook, DJ ;
Holbrook, A ;
McAlister, FA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (08) :771-778
[2]  
Buxton MJ, 1997, HEALTH ECON, V6, P217, DOI 10.1002/(SICI)1099-1050(199705)6:3<217::AID-HEC267>3.3.CO
[3]  
2-N
[4]  
Canadian Coordinating Office for Health Technology Assessment, 1997, GUID EC EV PHARM CAN
[5]   Does location of vertebral deformity within the spine influence back pain and disability? [J].
Cockerill, W ;
Ismail, AA ;
Cooper, C ;
Matthis, C ;
Raspe, H ;
Silman, AJ ;
O'Neill, TW .
ANNALS OF THE RHEUMATIC DISEASES, 2000, 59 (05) :368-371
[6]   Recommendations for the registration of agents used in the prevention and treatment of glucocorticoid-induced osteoporosis [J].
Compston, JE ;
Audran, M ;
Avouac, B ;
Bouvenot, G ;
Devogelaer, JP ;
Eastell, R ;
Fabris, F ;
Gennari, C ;
Jones, EA ;
Kaufman, JM ;
Lemmel, EM ;
Mazzuoli, G ;
Reid, DM ;
Ringe, JD ;
Vanhaelst, L ;
Ziegler, R ;
Reginster, JY .
CALCIFIED TISSUE INTERNATIONAL, 1996, 59 (05) :323-327
[7]   POPULATION-BASED STUDY OF SURVIVAL AFTER OSTEOPOROTIC FRACTURES [J].
COOPER, C ;
ATKINSON, EJ ;
JACOBSEN, SJ ;
OFALLON, WM ;
MELTON, LJ .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1993, 137 (09) :1001-1005
[8]  
Cranney A, 1999, ARTHRIT CARE RES, V12, P425, DOI 10.1002/1529-0131(199912)12:6<425::AID-ART11>3.0.CO
[9]  
2-A
[10]   RISK-FACTORS FOR HIP FRACTURE IN WHITE WOMEN [J].
CUMMINGS, SR ;
NEVITT, MC ;
BROWNER, WS ;
STONE, K ;
FOX, KM ;
ENSRUD, KE ;
CAULEY, JC ;
BLACK, D ;
VOGT, TM .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (12) :767-773